Prognostic significance of FAM3C in esophageal squamous cell carcinoma

Diagnostic Pathology

Xin-Yuan Guan²  Jianhua Fu³  Jian Sun¹  Pinzhu Huang⁴  Mengqing Li¹  Baozhu Zhang¹  Ying-Hui Zhu¹ 

[1] Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China;Department of Clinical Oncology, Faculty of Medicine, The University of Hong Kong, Hong Kong, China;Department of Thoracic Oncology, Sun Yat-sen University Cancer Center, Guangzhou, China;Department of Colorectal Surgery, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, China

关键词: EMT;    Prognosis;    ESCC;    FAM3C;   

Others  :  1233633
DOI  :  10.1186/s13000-015-0424-8

 received in 2015-09-14, accepted in 2015-10-09,  发布年份 2015

【 摘 要 】

Background

Family with sequence similarity 3, member C (FAM3C) has been identified as a novel regulator in epithelial-mesenchymal transition (EMT) and metastatic progression. However, the role of FAM3C in esophageal squamous cell carcinoma (ESCC) remains unexplored. The purpose of present study is to illustrate the role of FAM3C in predicting outcomes of patients with ESCC.

Methods

FAM3C expression was measured in ESCC tissues and the matched adjacent nontumorous tissues by quantitative real-time RT-PCR and Western blot analysis. The relationship between FAM3C expression and prognosis of ESCC patients was further evaluated by univariate and multivariate regression analyses. Univariate and multivariate analyses of the prognostic factors were performed using Cox proportional hazards model.

Results

The FAM3C mRNA expression was remarkably upregulated in ESCC compared with their nontumor counterparts (P < 0.001). In addition, high expression of FAM3C was significantly associated with pT stage (P = 0.014) , pN stage (P = 0.026) and TNM stage (P = 0.003). Kaplan-Meier analysis showed that the 7-year overall survival rate in the group with high expression of FAM3C was poorer than that in low expression group (32.0 versus 70.9 %; P < 0.001). Univariate and multivariate analyses demonstrated that FAM3C was an independent risk factor for overall survival. Moreover, Stratified analysis revealed that FAM3C expression could differentiate the prognosis of patients in early clinical stage (TNM stage I-II).

Conclusions

FAM3C expression was dramatically increased in ESCC and might serve as a valuable prognostic indicator for ESCC patients after surgery.

【 授权许可】

   
2015 Zhu et al.

【 图 表 】

Fig. 1.

Fig. 2.

【 参考文献 】

• [1]Kamangar F, Dores GM, Anderson WF. Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol. 2006; 24(14):2137-50.
• [2]Wheeler JB, Reed CE. Epidemiology of esophageal cancer. Surg Clin North Am. 2012; 92(5):1077-87.
• [3]Hongo M, Nagasaki Y, Shoji T. Epidemiology of esophageal cancer: orient to occident. Effects of chronology, geography and ethnicity. J Gastroenterol Hepatol. 2009; 24(5):729-35.
• [4]Stoner GD, Gupta A. Etiology and chemoprevention of esophageal squamous cell carcinoma. Carcinogenesis. 2001; 22(11):1737-46.
• [5]Xiao ZF, Yang ZY, Liang J, Miao YJ, Wang M, Yin WB et al.. Value of radiotherapy after radical surgery for esophageal carcinoma: a report of 495 patients. Ann Thorac Surg. 2003; 75(2):331-6.
• [6]Shimizu K, Hihara J, Yoshida K, Toge T. Clinical evaluation of low-dose cisplatin and 5-fluorouracil as adjuvant chemoradiotherapy for advanced squamous cell carcinoma of the esophagus. Hiroshima J Med Sci. 2005; 54(3):67-71.
• [7]Hagymasi K, Tulassay Z. Risk factors for esophageal cancer, and possible genetic background. Orv Hetil. 2009; 150(9):407-13.
• [8]Zhu Y, Xu G, Patel A, McLaughlin MM, Silverman C, Knecht K et al.. Cloning, expression, and initial characterization of a novel cytokine-like gene family. Genomics. 2002; 80(2):144-50.
• [9]Greinwald JH, Wayne S, Chen AH, Scott DA, Zbar RI, Kraft ML et al.. Localization of a novel gene for nonsyndromic hearing loss (DFNB17) to chromosome region 7q31. Am J Med Genet. 1998; 78(2):107-13.
• [10]Waerner T, Alacakaptan M, Tamir I, Oberauer R, Gal A, Brabletz T et al.. ILEI: a cytokine essential for EMT, tumor formation, and late events in metastasis in epithelial cells. Cancer Cell. 2006; 10(3):227-39.
• [11]Chaudhury A, Hussey GS, Ray PS, Jin G, Fox PL, Howe PH. TGF-beta-mediated phosphorylation of hnRNP E1 induces EMT via transcript-selective translational induction of Dab2 and ILEI. Nat Cell Biol. 2010; 12(3):286-93.
• [12]Gronborg M, Kristiansen TZ, Iwahori A, Chang R, Reddy R, Sato N et al.. Biomarker discovery from pancreatic cancer secretome using a differential proteomic approach. Mol Cell Proteomics. 2006; 5(1):157-71.
• [13]Gao ZH, Lu C, Wang ZN, Song YX, Zhu JL, Gao P et al.. ILEI: a novel marker for epithelial-mesenchymal transition and poor prognosis in colorectal cancer. Histopathology. 2014; 65(4):527-38.
• [14]Rice TW, Rusch VW, Ishwaran H, Blackstone EH. Cancer of the esophagus and esophagogastric junction: data-driven staging for the seventh edition of the American Joint Committee on Cancer/International Union Against Cancer Cancer Staging Manuals. Cancer. 2010; 116(16):3763-73.
• [15]Thiery JP, Acloque H, Huang RY, Nieto MA. Epithelial-mesenchymal transitions in development and disease. Cell. 2009; 139(5):871-90.
• [16]Grunert S, Jechlinger M, Beug H. Diverse cellular and molecular mechanisms contribute to epithelial plasticity and metastasis. Nat Rev Mol Cell Biol. 2003; 4(8):657-65.
• [17]Hugo H, Ackland ML, Blick T, Lawrence MG, Clements JA, Williams ED et al.. Epithelial--mesenchymal and mesenchymal--epithelial transitions in carcinoma progression. J Cell Physiol. 2007; 213(2):374-83.
• [18]Katsuno Y, Lamouille S, Derynck R. TGF-beta signaling and epithelial-mesenchymal transition in cancer progression. Curr Opin Oncol. 2013; 25(1):76-84.
• [19]Willis BC, Borok Z. TGF-beta-induced EMT: mechanisms and implications for fibrotic lung disease. Am J Physiol Lung Cell Mol Physiol. 2007; 293(3):L525-34.
• [20]Hussey GS, Chaudhury A, Dawson AE, Lindner DJ, Knudsen CR, Wilce MC et al.. Identification of an mRNP complex regulating tumorigenesis at the translational elongation step. Mol Cell. 2011; 41(4):419-31.
• [21]Hussey GS, Link LA, Brown AS, Howley BV, Chaudhury A, Howe PH. Establishment of a TGFbeta-induced post-transcriptional EMT gene signature. PLoS One. 2012; 7(12): Article ID e52624
• [22]Song Q, Sheng W, Zhang X, Jiao S, Li F. ILEI drives epithelial to mesenchymal transition and metastatic progression in the lung cancer cell line A549. Tumour Biol. 2014; 35(2):1377-82.
• [23]Du Plessis L, Dietzsch E, Van Gele M, Van Roy N, Van Helden P, Parker MI et al.. Mapping of novel regions of DNA gain and loss by comparative genomic hybridization in esophageal carcinoma in the Black and Colored populations of South Africa. Cancer Res. 1999; 59(8):1877-83.
• [24]Kwong D, Lam A, Guan X, Law S, Tai A, Wong J et al.. Chromosomal aberrations in esophageal squamous cell carcinoma among Chinese: gain of 12p predicts poor prognosis after surgery. Hum Pathol. 2004; 35(3):309-16.
• [25]Lahsnig C, Mikula M, Petz M, Zulehner G, Schneller D, van Zijl F et al.. ILEI requires oncogenic Ras for the epithelial to mesenchymal transition of hepatocytes and liver carcinoma progression. Oncogene. 2009; 28(5):638-50.
• [26]Chambers AF, Groom AC, MacDonald IC. Dissemination and growth of cancer cells in metastatic sites. Nat Rev Cancer. 2002; 2(8):563-72.
• [27]Yang J, Mani SA, Donaher JL, Ramaswamy S, Itzykson RA, Come C et al.. Twist, a master regulator of morphogenesis, plays an essential role in tumor metastasis. Cell. 2004; 117(7):927-39.
• [28]Leptin M, Grunewald B. Cell shape changes during gastrulation in Drosophila. Development. 1990; 110(1):73-84.
• [29]Nguyen DX, Massague J. Genetic determinants of cancer metastasis. Nat Rev Genet. 2007; 8(5):341-52.
• [30]Valastyan S, Weinberg RA. Tumor metastasis: molecular insights and evolving paradigms. Cell. 2011; 147(2):275-92.